Login to Your Account



In The Clinic NEWS

Oncothyreon Inc. shares fell 17.3 percent Tuesday after the company revealed that tecemotide, an immunotherapy it licensed to Merck KGaA, failed to improve overall survival or impact secondary endpoints progression-free survival, time to progression or time to failure in a phase I/II study.

Interim phase II data showing that an eight-week course of Achillion Pharmaceuticals Inc.'s NS5A inhibitor, ACH-3102, and Sovaldi (sofosbuvir, Gilead Sciences Inc.) in 12 hepatitis C virus (HCV) genotype 1 patients resulted in a complete sustained virologic response rate four weeks after treatment (SVR4) pushed company shares (Nasdaq:ACHN) up 9.6 percent to close at $9.25 Friday.

A morsel of phase IIa data from Arrowhead Research Corp. left investors wanting more and sparked analyst speculation about the potential of the firm's ARC-520, an RNAi-based candidate for hepatitis B virus (HBV).
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: